BridgeBio’s Attruby (Acoramidis): A New, More Potent TTR Stabilizer for ATTR-CM
XTalks
NOVEMBER 26, 2024
BridgeBio has been highly active in the genetic diseases space. Its investigational therapy infigratinib recently received Breakthrough Therapy designation, becoming the first-ever potential treatment for achondroplasia — a genetic condition affecting bone growth — to achieve this milestone.
Let's personalize your content